ICU Medical (NASDAQ:ICUI) Sets New 52-Week High – Here’s What Happened

ICU Medical, Inc. (NASDAQ:ICUI)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $160.62 and last traded at $159.28, with a volume of 256378 shares traded. The stock had previously closed at $154.97.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ICUI shares. Piper Sandler cut their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a report on Monday, June 15th. BTIG Research began coverage on ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price target on the stock. Finally, Weiss Ratings raised ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $168.40.

ICU Medical Trading Down 2.2%

The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The firm’s 50 day moving average price is $135.02 and its 200 day moving average price is $138.67. The stock has a market capitalization of $3.80 billion, a P/E ratio of 82.10, a P/E/G ratio of 2.23 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.ICU Medical’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period last year, the firm earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Maryland State Retirement & Pension System grew its holdings in ICU Medical by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after purchasing an additional 70 shares during the last quarter. California Public Employees Retirement System lifted its stake in ICU Medical by 0.3% in the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after purchasing an additional 90 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after purchasing an additional 100 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after buying an additional 101 shares during the last quarter. Finally, Lido Advisors LLC grew its stake in shares of ICU Medical by 4.5% during the fourth quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock valued at $354,000 after buying an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.